Every Form 4 that Xtant Medical Holdings, Inc. (XTNT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow XTNT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XTNT filings page.
Xtant Medical Holdings, Inc. (symbol: XTNT) is the issuer of record for a Form 4 filing submitted to the SEC.
Xtant Medical Holdings, Inc. (XTNT) reported that director John K. Bakewell received a grant of 215,517 deferred stock units (DSUs) of common stock at no cash cost, classified as a grant/award acquisition. The DSUs vest on August 15, 2027, conditioned on his continued service as a director, with settlement of the vested shares deferred to a later date under the DSU award agreement. After this award, he holds 1,129,633 shares of common stock directly, including 681,087 shares issuable upon settlement of previously granted DSUs.
Xtant Medical Holdings, Inc. (symbol: XTNT) is the issuer of record for a Form 4 filing submitted to the SEC.
Xtant Medical Holdings, Inc. (symbol: XTNT) is the issuer of record for a Form 4 filing submitted to the SEC.
Xtant Medical Holdings, Inc. (symbol: XTNT) is the issuer of record for a Form 4 filing submitted to the SEC.
Xtant Medical Holdings, Inc. (XTNT) reported equity compensation changes for Chief Operating Officer Mark A. Schallenberger. He received a grant of 450,000 deferred stock units (DSUs), which will vest in four equal installments of 112,500 shares on August 15 of each year from 2027 through 2030, conditioned on continued employment. Settlement of the vested DSUs into common stock will occur at a later date under the award terms. Separately, 7,070 shares of common stock were withheld at $0.31 per share to satisfy tax withholding obligations upon vesting and settlement of restricted stock units.
Xtant Medical Holdings, Inc. reported that its CFO and Assistant Secretary, Scott C. Neils, received a grant of 400,000 deferred stock units (DSUs) of common stock. These DSUs vest in four equal installments of 100,000 shares on each of August 15, 2027, 2028, 2029, and 2030, conditioned on his continued employment, with settlement to occur at a later date. On the same date, 28,155 shares of common stock were withheld at $0.31 per share to cover tax withholding obligations upon vesting and settlement of prior restricted stock unit awards. In total, Neils now has 869,878 shares issuable upon vesting and settlement of RSU and DSU awards, all subject to continued employment through their respective vesting dates.
Xtant Medical Holdings, Inc. reported that President and CEO Sean E. Browne received a grant of 550,000 shares of Common Stock in the form of deferred stock units under the Amended and Restated 2023 Equity Incentive Plan. These DSUs will vest in four equal installments of 137,500 shares on each of August 15, 2027, 2028, 2029, and 2030, conditioned on his continued employment, with settlement of vested shares deferred to a later date. A separate transaction shows 10,605 shares of Common Stock withheld at $0.31 per share to satisfy tax withholding obligations upon vesting and settlement of existing restricted stock unit awards. Footnote disclosure states that Browne has an aggregate of 1,720,123 shares issuable upon vesting and settlement of RSU and DSU awards, subject to future service-based vesting.
Xtant Medical Holdings Chief Operating Officer Mark A. Schallenberger reported a tax-related share disposition. On this Form 4, 7,709 shares of common stock at $0.58 per share were withheld by the company to cover tax obligations upon vesting and settlement of restricted stock units. After this withholding, he reports ownership of 663,157 shares of common stock, which includes large blocks of RSU and DSU awards that will vest only if he remains employed through future vesting dates.
Xtant Medical Holdings CFO and Assistant Secretary Neils C. Scott reported an automatic tax-withholding transaction in company stock. On 01/15/2026, 8,084 shares of common stock were withheld by the issuer at $0.65 per share to cover tax obligations triggered by the vesting and settlement of restricted stock unit awards.
After this transaction, Scott beneficially owned 843,381 shares of Xtant, which includes 498,914 shares issuable upon vesting and settlement of RSU or DSU awards under the Amended and Restated 2023 Equity Incentive Plan and 62,974 shares issuable upon vesting and settlement of RSU awards under the Amended and Restated 2018 Equity Incentive Plan, in each case conditioned on continued employment through the respective vesting dates.
Xtant Medical Holdings, Inc. director reports updated equity holdings through an amended Form 4. The filing shows the grant of 158,228 shares of common stock in the form of deferred stock units (DSUs) at a price of $0 on 11/15/2025 under the Amended and Restated 2023 Equity Incentive Plan. These DSUs will vest on November 15, 2026, if the individual continues to serve as a director through that date, and each DSU represents a contingent right to receive one share of common stock. Following this transaction, the reporting person beneficially owns 914,116 shares, which includes 465,570 shares issuable upon settlement of outstanding DSU awards, each subject to service-based vesting. The amendment states that its purpose is to correct the number of shares shown as beneficially held in the ownership column.
Xtant Medical Holdings, Inc. director equity grant reported
A director of Xtant Medical Holdings, Inc. (XTNT) reported receiving 553,797 shares of common stock on November 15, 2025 through a deferred stock unit (DSU) award under the company’s Amended and Restated 2023 Equity Incentive Plan. The DSUs will vest on November 15, 2026, provided the director remains on the board through that date, and each DSU represents a contingent right to receive one share of common stock, with settlement deferred to a later date under the award terms.
Following this award, the director beneficially owns 7,515,570 shares on a direct basis, which includes 1,520,215 shares issuable upon settlement of DSUs that are subject to continued service-based vesting conditions.
Xtant Medical Holdings (XTNT) reported an insider equity grant to a director dated November 15, 2025. The director received 158,228 deferred stock units (DSUs) of common stock at a stated price of $0 under the company’s Amended and Restated 2023 Equity Incentive Plan. Following this grant, the director beneficially owned 517,619 shares directly, including 465,570 shares issuable upon settlement of DSUs, and 1,015,272 shares indirectly through The Platinum Legacy Trust. The new DSU award will vest on November 15, 2026 if the director remains on the board, with settlement of the underlying shares deferred under the DSU award agreement.
Xtant Medical Holdings, Inc. reported that one of its directors received a new equity award in the form of deferred stock units. On November 15, 2025, the director was granted 158,228 deferred stock units (DSUs) of common stock at a price of $0 under the company’s Amended and Restated 2023 Equity Incentive Plan. These DSUs will vest on November 15, 2026, as long as the individual continues to serve as a director through that date. Each DSU represents the right to receive one share of common stock, with actual share delivery deferred to a later date under the award agreement.
Xtant Medical Holdings, Inc. (XTNT) reported that one of its directors received a new equity award in the form of deferred stock units. On November 15, 2025, the director was granted 158,228 deferred stock units (DSUs) of common stock at a reported price of $0 per share. These DSUs will vest on November 15, 2026, provided the individual remains a director through that date. After vesting, the underlying shares will be settled at a later time according to the DSU award agreement. Following this grant, the director beneficially owns 158,228 shares in the form of DSUs under Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan.
Xtant Medical Holdings, Inc. (XTNT) reported that one of its directors received a grant of 158,228 deferred stock units (DSUs) of common stock on November 15, 2025. The DSUs were granted at a price of $0 under the company’s Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, provided the director continues to serve on the board through that date. Each DSU represents the right to receive one share of common stock, with settlement of the vested shares deferred to a later date in line with the DSU award agreement. Following this grant, the reporting person beneficially owns 158,228 shares in the form of DSUs under the plan.
Xtant Medical Holdings, Inc. reported new equity awards for its President and CEO and director on a Form 4. On 11/15/2025, the executive acquired 394,937 shares of common stock at $0, bringing total beneficial ownership to 2,575,274 shares, held directly. These shares are linked to a deferred stock unit award that vests in installments: 98,734 shares on each of November 15, 2026, 2027, and 2028, and 98,735 shares on November 5, 2029, subject to continued employment.
The filing also reports a grant of 789,874 performance stock units (PSUs), representing the maximum of 200% of a 394,937-share target. Each PSU can convert into one share of common stock, vesting in one-third increments based on stock price performance over a three-year period and additional service-based conditions. The executive’s holdings include 1,213,677 shares issuable upon vesting and settlement of restricted stock units and deferred stock units under the company’s 2023 equity incentive plan.
Xtant Medical Holdings (XTNT) reported new equity awards to its Chief Operating Officer on a Form 4. On 11/15/2025, the officer acquired 292,253 shares of common stock at a price of $0 through a deferred stock unit (DSU) award, bringing total beneficial ownership of common stock to 670,866 shares held directly. The DSU grant will vest in four installments: 73,063 shares on each of November 15, 2026, November 15, 2027, and November 15, 2028, and 73,064 shares on November 5, 2029, subject to continued employment, with settlement of shares deferred under the award terms.
The filing also reports a grant of 584,506 performance stock units (PSUs) at a price of $0, which represent a contingent right to receive an equal number of common shares. These PSUs can vest in one-third increments based on stock price performance goals over a three-year period and additional service-based conditions, with 584,506 derivative securities beneficially owned following the grant. The footnotes note that existing holdings include shares issuable under prior RSU and DSU awards from the company’s equity incentive plans.
Xtant Medical Holdings reported an equity award to its CFO and Assistant Secretary. On 11/15/2025, the executive received 263,291 deferred stock units (DSUs) at a price of $0, increasing his beneficial ownership of common stock to 851,465 shares held directly.
The DSUs vest in installments of 65,822 shares on each of November 15, 2026, November 15, 2027, and November 15, 2028, and 65,825 shares on November 5, 2029, subject to continued employment, with settlement deferred under the award terms. The filing also reports 526,582 performance stock units (PSUs), representing 200% of a 263,291-share target, which can convert into common stock based on stock price performance over a three-year period and additional service-based vesting conditions.